Share ownership Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 16:04:54 21/01/2026 GMT			5-day change	1st Jan Change
358.22 ^USD	+0.76%		-2.16%	-9.73%

01-20	RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing	MT

Share class: Alnylam Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	129,457,156	128,426,080 ( 99.2 %)	0	99.2 %

Major shareholders: Alnylam Pharmaceuticals, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 12.69 %	16,763,085	12.69 %	6 666 M $
Capital Research & Management Co. (World Investors) 12.44 %	16,434,253	12.44 %	6 535 M $
Vanguard Fiduciary Trust Co. 10.27 %	13,565,452	10.27 %	5 394 M $
BlackRock Advisors LLC 5.957 %	7,870,661	5.957 %	3 130 M $
Capital Research & Management Co. (Global Investors) 5.467 %	7,222,840	5.467 %	2 872 M $
JPMorgan Investment Management, Inc. 3.439 %	4,543,770	3.439 %	1 807 M $
STATE STREET CORPORATION 2.332 %	3,081,475	2.332 %	1 225 M $
Baillie Gifford & Co. 2.111 %	2,789,356	2.111 %	1 109 M $
Geode Capital Management LLC 1.892 %	2,499,242	1.892 %	994 M $
Dodge & Cox 1.757 %	2,321,230	1.757 %	923 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	88.01%
Other	8.2%
State Street Corp.	2.33%
Regeneron Pharmaceuticals, Inc.	1.05%
Individuals	0.43%
Schweizerische Nationalbank	0.28%
Sumitomo Mitsui Trust Group, Inc.	0.24%
Polar Capital Holdings Plc	0.19%
SEI Investments Co.	0.08%
Skandinaviska Enskilda Banken AB	0.06%
Manulife Financial Corp.	0.05%
Swedbank AB	0.05%
Governments	0.05%
Danske Bank A/S	0.04%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Zurich Insurance Group AG	0.02%
Cullen/Frost Bankers, Inc.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	80.98%
United Kingdom	9.1%
Canada	1.68%
Norway	1.66%
Bermuda	1.48%
France	1.1%
Switzerland	0.82%
Cayman Islands	0.66%
Japan	0.57%
Sweden	0.52%
Individuals	0.43%
Australia	0.37%
South Korea	0.29%
Ireland	0.22%
Belgium	0.21%
Luxembourg	0.2%
Germany	0.19%
Denmark	0.12%
Netherlands	0.11%
Singapore	0.06%
Spain	0.05%
Finland	0.05%
China	0.05%
Hong Kong	0.04%
Austria	0.03%
Taiwan	0.03%
Italy	0.03%
South Africa	0.03%
Puerto Rico	0.01%
India	0.01%
Slovenia	0.01%
Thailand	0.01%

Based on 1000 largest holdings

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Employees

2,230

Sector

Pharmaceuticals

Calendar

02-11 - Q4 2025 Earnings Release (Projected)

More about the company